Conference
September 13, 2021

ASCO 2019 Demographics, Chicago, IL

Conference
September 25, 2019

ASCO 2019 Demographics, Chicago, IL

Author

The American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 31 – June 4, 2019 in Chicago, IL.  ASCO recently released their demographics for 2019 and we are going to compare the numbers from 2018.

The American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 31 – June 4, 2019 in Chicago, IL.  ASCO recently released their demographics for 2019 and we are going to compare the numbers from 2018.

In 2019, there was a total of 42,500 attendees, a 4.4% increase from 2018 which had a total of 40,700 attendees.  Out of the 42,500 attendees, 34,250 were professionals and 6,216 were exhibitors.  The top countries in attendance in 2019 are the United States and China whereas in 2018, it was the US and Canada.  This year, 55% of attendees were international while in 2018, 2% of guests were international.  It’s clear that the numbers in 2019 have greatly increased since 2018 which is wonderful to see.

People attend the ASCO Annual Meeting every year and these increasing numbers show that more people have come together to meet each other, take in new information, and grow more within their skills and fields.  Guests’ roles ranged from oncologists, pharmacists, biologists, researchers, and more.

Connecting with our clients is always a pleasure and these conferences give us the opportunity to say hello and touch base. We are always looking to attend conferences. Follow us on Twitter to stay up to date on our upcoming events or visit our website.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.